ArticleBMJ public health2025
Population-based cross-sectional seroprevalence study of SARS-CoV-2 infection in urban residential areas in Ghana.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Inequalities and determinants of unmet need for SARS-CoV-2 testing in Ghana, Burkina Faso and Madagascar (2020 - 2021).Communications medicine · 2026Article
- Seroprevalence of endemic and emergent coronaviruses among SARS-COV-2 patients and healthcare workers in Abidjan, Côte d'Ivoire.BMC infectious diseases · 2026Article
- Baseline Procalcitonin and C-Reactive Protein Levels in Asymptomatic Individuals From West Africa With and WithoutOpen forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Estimates of SARS-CoV-2-specific IgG antibodies using robust designs and serological assays have been a key component in assessing and reporting the overall occurrence of COVID-19 infection burden in the general population. The objective of this study was to estimate the seroprevalence and characteristics of COVID-19 infection transmission in Ghana. Methods: We conducted a cross-sectional survey using a two-stage stratified random sampling of community household members from February 2021 to February 2022 in Ghana, to estimate SARS-CoV-2 seroprevalence. Bayesian models with poststratification weighting of the demographic structure of the sample population were used for seroprevalence estimates, accounting for the uncertainty of diagnostic assay in a hierarchical model. Exposure-wide analysis was performed to evaluate the characteristics of the widespread SARS-CoV-2 infection. Results: On average, two members per household were recruited from 299 households in Accra, 348 in Kumasi and 268 in Tamale. Test-performance adjusted seroprevalence estimate was 42.8% (95% CI 37.5% to 48.5%) in Kumasi, 52.6% (95% CI 46.5% to 59.4%) in Accra and 81.7% (95% CI 74.6% to 89.0%) in Tamale. The poststratification for age, sex and household structure raised the overall seroprevalence estimates marginally to 43.9% (95% CI 38.1% to 50.1%) in Kumasi, 53.3% (95% CI 46.9% to 60.1%) in Accra and 84.7% (95% CI 76.4% to 95.6%) in Tamale. These estimates indicate that COVID-19 surveillance and reporting largely underestimates the true extent of infections and herd immunity in Ghana, with an estimated infection-to-case ratio of 19:1 in Kumasi; 85:1 in Accra and 49:1 in Tamale, as of March 2021, October 2021, February 2022, respectively. The seroprevalence estimate was not affected by the sex and age of the study participants. In an exposure-wide analysis, after adjusting for temporal biases in sample collection, age and sex, the average number of contacts per day was the only significant exposure variable associated with increased SARS-CoV-2 seropositivity, with an OR between 1.5 and 1.8. Conclusions: Our data highlight a sustained national transmission of COVID-19 disease through individual contacts and suggests a situation of asymptomatic endemic circulation of the SARS-CoV-2 virus and potential herd immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.